COMMUNIQUÉS West-GlobeNewswire

Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®
30/12/2024
Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025 BRAINTREE, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular [...]
Entourage Health Corp. Enters into Arrangement Agreement for Going-Private Transaction
30/12/2024
TORONTO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE: 4WE) (the “ Company ” or “ Entourage ”) is pleased to announce that it has entered into a definitive arrangement [...]
Treace Expands Reach into High-Volume Osteotomy Market with Second MIS Osteotomy Platform, Percuplasty™ Percutaneous 3D Bunion Correction® Procedure
30/12/2024
Positions Treace to Significantly Increase Share of Overall Bunion Market and Expand Surgeon Customer Base PONTE VEDRA, Fla., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) ( [...]
UPDATE – Alignment Healthcare to Present at the 43rd Annual J.P. Morgan Healthcare Conference
30/12/2024
ORANGE, Calif. , Dec. 30, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan [...]
Hematology Oncology of Indiana Physician Research Presented at 66th ASH Annual Meeting
30/12/2024
INDIANAPOLIS, IN., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Board-certified medical oncologists, M. Sarfraz Nawaz, MD and Ruemu E. Birhiray, MD from community oncology practice Hematology Oncology of Indiana (HOI), a partner [...]
Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia
30/12/2024
RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1 imaging trial Financial incentives to be paid to RAD upon meeting clinical [...]
Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025
30/12/2024
FREMONT, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved a stock repurchase program [...]
KALA BIO Announces $10,750,000 Private Placement
30/12/2024
ARLINGTON, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare [...]
Inspire Medical Systems, Inc. to Present at 43rd Annual J.P. Morgan Healthcare Conference
30/12/2024
MINNEAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive [...]
Evaxion announces plan to implement ADS ratio change
30/12/2024
COPENHAGEN, Denmark, December 30, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it plans to [...]
Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth
30/12/2024
Sale process will help enable next stage of product development Secures up to $10.25 million in new financing to support ongoing business operations SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc [...]
Hit Refresh in the New Year with Tilray's Premium Non-Alcohol Beverage Lineup
30/12/2024
Explore Tilray’s Range of Non-Alcohol Drinks, from Sparkling Waters to Hemp-Derived Delta-9 THC and IPA-Inspired Beverages NEW YORK, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc . (Nasdaq: TLRY; TSX: TLRY), a [...]
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
30/12/2024
ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse) ACCORD-2 Phase 3 trial achieves key secondary endpoint compared to placebo (p=0.001, [...]
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
30/12/2024
Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its pivotal Phase III advanced liver cancer study Ramat Gan, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) -- [...]
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
30/12/2024
Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility DURHAM, N.C., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose [...]
Orion and Marinus terminate agreement for ganaxolone in Europe
30/12/2024
ORION CORPORATION PRESS RELEASE 30 DECEMBER 2024 at 14.00 EET Orion and Marinus terminate agreement for ganaxolone in Europe Orion Corporation (“Orion”) and Marinus Pharmaceuticals, Inc. (“Marinus”) have decided to [...]
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies
30/12/2024
Raanana, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
European Commission approves RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
30/12/2024
This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line treatment of patients with EGFR-mutated NSCLC 1 In the Phase 3 MARIPOSA study, amivantamab plus [...]
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
30/12/2024
Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onasemnogene abeparvovec [...]

Pages